Stock Compensation Plan (Tables)

12 Months Ended

Dec. 31, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Valuation Assumptions

For market-based restricted stock units granted during 2024, 2023 and 2022 valued using the Monte Carlo Simulation valuation model, we used the following assumptions:

	Year ended December 31
	2024		2023		2022
Risk-free interest rate	4.3	%	4.5	%	2.0	%
Expected dividend yield	—	%	—	%	—	%
Term	3 years		2.97 years		3 years
Expected volatility	58.8	%	56.3	%	42.5	%

Schedule of Stock Option Activity

A summary of stock option activity and weighted average exercise prices follows:

	Options	Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value as of December 31, 2024
Outstanding at January 1, 2024	10,501	$	51.58
Granted	—	—
Forfeited	—	—
Exercised	—	—
Expired	(3,907)	35.44
Outstanding at December 31, 2024	6,594	$	61.14	0.21	$	—
Options exercisable at December 31, 2024	6,594	$	61.14	0.21	$	235,956

Schedule of Restricted Stock Activity

The following table summarizes the restricted stock and restricted stock unit activity and weighted-average grant date fair values for the year ended December 31, 2024:

	Shares	Weighted-Average Grant Date Fair Value
Non-vested at January 1, 2024	1,457,418	$	32.06
Granted	830,880	23.62
Forfeited	(416,183)	40.95
Vested	(592,761)	28.53
Non-vested at December 31, 2024	1,279,354	$	25.40

Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount

The following table summarizes total stock-based compensation expense for each of the line items on our consolidated statement of operations:

	Years ended December 31,
	2024		2023		2022
Cost of Sales
Product	$	1,080	$	1,150	$	889
Service	388		185		161
Total cost of sales	1,468		1,335		1,050
Operating Expenses
Selling, general and administrative	8,343		14,198		9,656
Research and development	1,878		2,300		2,611
Total operating expenses	10,221		16,498		12,267
Total stock-based compensation	$	11,689	$	17,833	$	13,317